Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3817-3825

  Schwaederle, Maria ^a   Zhao, Melissa ^a   Lee, J Jack ^b   Eggermont, Alexander M ^d,e   Schilsky, Richard L ^c,e   Mendelsohn, John ^b,e   Lazar, Vladimir ^d,e   Kurzrock, Razelle ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Worldwide Innovative Network in Personalized Cancer Medicine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER MORTALITY; CANCER THERAPY; CYTOTOXICITY; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; SYSTEMATIC REVIEW; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TRENDS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE;

EID: 84946053976     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.5997     Document Type: Article

References (37)

1. Stewart DJ, Kurzrock R: Cancer: The road to Amiens. J Clin Oncol 27:328-333, 2009
2. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
3. Dancey JE, Bedard PL, Onetto N, et al: The genetic basis for cancer treatment decisions. Cell 148:409-420, 2012
4. Wong KM, Hudson TJ, McPherson JD: Unraveling the genetics of cancer: Genome sequencing and beyond. Annu Rev Genomics Hum Genet 12:407-430, 2011
5. Barrett JC, Frigault MM, Hollingsworth S, et al: Are companion diagnostics useful? Clin Chem 59:198-201, 2013
6. Montemurro F, Valabrega G, Aglietta M: Trastuzumab treatment in breast cancer. N Engl J Med 354:2186, 2006
7. Hudis CA: Trastuzumab: Mechanism of action and use in clinical practice. N Engl J Med 357:39-51, 2007
8. Incorvati JA, Shah S, Mu Y, et al: Targeted therapy for HER2 positive breast cancer. J Hematol OncolJ Hematol Oncol 6:38, 2013
9. Barbany G, Höglund M, Simonsson B: Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med 347:539-540, 2002
10. Boros LG, Lee WN, Cascante M: Imatinib and chronic-phase leukemias. N Engl J Med 347:67-68, 2002
11. Druker BJ, Guilhot F, O'Brien SG, et al: Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006
12. Westin JR, Kurzrock R: It's about time: Lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther 11:2549-2555, 2012
13. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
14. Dalle S, Poulalhon N, Thomas L: Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 365:1448-1450, 2011
15. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
16. Gonzalez De Castro D, Clarke PA, Al-Lazikani B, et al: Personalized cancer medicine: Molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 93:252-259, 2013
17. Said R, Hong DS, Warneke CL, et al: P53 mutations in advanced cancers: Clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 4:705-714, 2013
18. Janku F, Wheler JJ, Naing A, et al: PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73:276-284, 2013
19. Janku F, Berry DA, Gong J, et al: Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res 18:6356-6363, 2012
20. Collins I, Workman P: New approaches to molecular cancer therapeutics. Nat Chem Biol 2:689-700, 2006
21. Hoelder S, Clarke PA, Workman P: Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol Oncol 6:155-176, 2012
22. Tsimberidou AM, Iskander NG, Hong DS, et al: Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. Clin Cancer Res 18:6373-6383, 2012
23. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558, 2002
24. Der Simonian R, Kacker R: Random-effects model for meta-analysis of clinical trials: An update. Contemp Clin Trials 28:105-114, 2007
25. Henary H, Hong DS, Falchook GS, et al: Melanoma patients in a phase I clinic: Molecular aberrations, targeted therapy and outcomes. Ann Oncol 24:2158-2165, 2013
26. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al: Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-4883, 2010
27. Weiss GJ, Liang WS, Demeure MJ, et al: A pilot study using next-generation sequencing in advanced cancers: Feasibility and challenges. PloS One 8:e76438, 2013
28. Tsimberidou AM, Wen S, Hong DS, et al: Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: Validation and landmark analyses. Clin Cancer Res 20:4827-4836, 2014
29. Munoz J, Swanton C, Kurzrock R: Molecular profiling and the reclassification of cancer: Divide and conquer. Am Soc Clin Oncol Educ Book 2013:127-134, 2013
30. Michiels S, Piedbois P, Burdett S, et al: Metaanalysis when only the median survival times are known: A comparison with individual patient data results. Int J Technol Assess Health Care 21:119-125, 2005
31. Lee SM: Is EGFR expression important in non-small cell lung cancer? Thorax 61:98-99, 2006
32. Araki T, Yashima H, Shimizu K, et al: Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol 6:407-421, 2012
33. Lee K-H, Lee K-Y, Jeon Y-J, et al: Gefitinib in selected patients with pre-treated non-small-cell lung cancer: Results from a phase IV, multicenter, non-randomized study (SELINE). Tuberc Respir Dis (Seoul) 73:303-311, 2012
34. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
35. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
36. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
37. Shyr D, Liu Q: Next generation sequencing in cancer research and clinical application. Biol Proced Online 15:4, 2013